Publications by authors named "Christopher A Eide"

61Publications

Response and Resistance to BCR-ABL1-Targeted Therapies.

Cancer Cell 2020 04;37(4):530-542

Division of Hematology/Medical Oncology, Knight Cancer Insitute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.03.006DOI Listing
April 2020

Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

Proc Natl Acad Sci U S A 2019 12 21;116(49):24593-24599. Epub 2019 Nov 21.

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1904091116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900505PMC
December 2019

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.

Cancer Res 2019 09 16;79(18):4744-4753. Epub 2019 Jul 16.

Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-1236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893872PMC
September 2019

Functional genomic landscape of acute myeloid leukaemia.

Nature 2018 10 17;562(7728):526-531. Epub 2018 Oct 17.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-018-0623-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280667PMC
October 2018

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Leukemia 2018 09 6;32(9):2025-2028. Epub 2018 Aug 6.

Department of Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0225-7
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0225-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168939PMC
September 2018

Understanding cancer from the stem cells up.

Nat Med 2017 06;23(6):656-657

Howard Hughes Medical Institute Portland, Oregon, USA, and in the Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health &Science University, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4353DOI Listing
June 2017

Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.

Pediatr Blood Cancer 2017 Oct 14;64(10). Epub 2017 Apr 14.

Department of Pediatrics, Doernbecher Children's Hospital, Papé Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26553DOI Listing
October 2017

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Cell Rep 2017 03;18(13):3204-3218

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437102PMC
March 2017

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sci Transl Med 2016 08;8(354):354ra114

Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA. Division of Pediatric Hematology and Oncology, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaf5309DOI Listing
August 2016

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Proc Natl Acad Sci U S A 2015 Sep 8;112(39):E5381-90. Epub 2015 Sep 8.

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239; Howard Hughes Medical Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1515281112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593101PMC
September 2015

Therapeutically Targetable ALK Mutations in Leukemia.

Cancer Res 2015 Jun;75(11):2146-50

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/75/11/2146.full.pd
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-14-1576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453002PMC
June 2015

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Curr Hematol Malig Rep 2015 Jun;10(2):158-66

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-015-0248-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447524PMC
June 2015

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Sci Transl Med 2014 Sep;6(252):252ra121

Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3009073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162097PMC
September 2014

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Clin Cancer Res 2014 Apr 16;20(8):2092-103. Epub 2014 Jan 16.

Authors' Affiliations: Knight Cancer Institute; Division of Hematology & Medical Oncology; Departments of Cell and Developmental Biology and Molecular and Medical Genetics, Oregon Health and Science University; Howard Hughes Medical Institute, Portland, Oregon; Oncotide Pharmaceuticals, Research Triangle Park; Duke University Medical Center, Durham, North Carolina; and Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/20/8/2092.full
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989420PMC
April 2014

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Proc Natl Acad Sci U S A 2013 Nov 11;110(48):19519-24. Epub 2013 Nov 11.

Knight Cancer Institute, Howard Hughes Medical Institute, and Departments of Biochemistry and Molecular Biology and Cell and Developmental Biology, Oregon Health and Sciences University, Portland, OR 97239.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1319583110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845150PMC
November 2013

Kinase inhibitor therapy in CML: it's what's inside that counts.

Oncotarget 2013 Sep;4(9):1332-3

Howard Hughes Medical Institute; Division of Hematology and Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824533PMC
http://dx.doi.org/10.18632/oncotarget.1271DOI Listing
September 2013

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Cancer Res 2013 Sep 25;73(18):5775-86. Epub 2013 Jul 25.

Authors' Affiliations: OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; Howard Hughes Medical Institute, Chevy Chase, Maryland; Huntsman Cancer Institute; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, Utah; Novartis Institutes for BioMedical Research, Basel, Switzerland; and Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894913PMC
September 2013

HitWalker: variant prioritization for personalized functional cancer genomics.

Bioinformatics 2013 Feb 9;29(4):509-10. Epub 2013 Jan 9.

Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btt003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570211PMC
February 2013

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

Clin Cancer Res 2011 Jan 22;17(2):212-21. Epub 2010 Nov 22.

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-3314DOI Listing
January 2011

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.

Blood 2009 Oct 25;114(16):3459-63. Epub 2009 Aug 25.

Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-10-113969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765681PMC
October 2009

New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?

Clin Lymphoma Myeloma 2008 Mar;8 Suppl 3:S107-17

Oregon Health & Science University Cancer Institute, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2008.s.006DOI Listing
March 2008

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

Expert Opin Investig Drugs 2008 Jun;17(6):865-78

Oregon Health & Science University Cancer Institute, Howard Hughes Medical Institute, Portland, Oregon 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.6.865DOI Listing
June 2008

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

Proc Natl Acad Sci U S A 2008 Apr 26;105(14):5507-12. Epub 2008 Mar 26.

Division of Hematology and Medical Oncology, Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0800587105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291110PMC
April 2008

GATA-2 functions downstream of BMPs and CaM KIV in ectodermal cells during primitive hematopoiesis.

Dev Biol 2007 Oct 16;310(2):454-69. Epub 2007 Aug 16.

Department of Cell and Developmental Biology, Oregon Health and Science University, School of Medicine, Portland, OR 97239-3098, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ydbio.2007.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2049090PMC
October 2007

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

Blood 2007 Oct 11;110(7):2242-9. Epub 2007 May 11.

Howard Hughes Medical Institute, Chevy Chase, MD, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-03-06
Publisher Site
http://dx.doi.org/10.1182/blood-2007-03-066936DOI Listing
October 2007

Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.

Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S120-30

Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2007.s.012DOI Listing
March 2007